Welcome to our dedicated page for Neuphoria Therapeutics SEC filings (Ticker: NEUP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neuphoria Therapeutics Inc. (NEUP) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed clinical-stage biotechnology company, Neuphoria uses its Forms 10-K, 10-Q and 8-K, along with proxy materials and other statements, to report on its business, pipeline, governance and material events.
For NEUP, current reports on Form 8-K are especially informative. Recent 8-K filings have described outcomes from the AFFIRM-1 Phase 3 trial of BNC210 in social anxiety disorder, the decision to discontinue further development of the SAD program, and the company’s plans for a full strategic review of its operations and portfolio. Other 8-Ks detail the adoption of a limited-duration stockholder rights plan, notices from The Nasdaq Stock Market LLC regarding listing rule compliance, and the holding of the company’s annual meeting of stockholders.
Neuphoria’s filings also include information on strategic and governance matters. A definitive proxy statement on Schedule 14A outlines proposals for director elections, auditor ratification, and advisory votes on executive compensation and its frequency. Additional 8-K disclosures describe changes in executive roles and the entry into a consulting agreement with the company’s former full-time CEO to serve as interim CEO during the strategic review and potential strategic transaction process.
Investors can use NEUP’s periodic reports, when available, to review financial statements, license revenue, research and development spending, and cash position, as well as risk factor discussions related to its CNS drug development programs and collaborations with partners such as Merck & Co., Inc. These documents also provide context on Neuphoria’s single operating segment focused on allosteric ion channel modulators.
On Stock Titan, NEUP filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain the key points in lengthy filings, highlight important clinical and strategic disclosures, and make it easier to locate information on topics such as trial outcomes, rights plans, annual meeting results, and material agreements. This allows users to quickly understand what each filing means for Neuphoria’s business and capital markets profile without reading every page in full.
Neuphoria Therapeutics (NEUP) reported topline results from its AFFIRM-1 Phase 3 trial of BNC210 in social anxiety disorder, stating the study did not meet its primary endpoint on the SUDS score during the public speaking performance phase. Analyses of secondary endpoints also did not show statistically significant differences versus placebo.
The company noted BNC210’s safety and tolerability remained favorable and consistent with prior studies. Neuphoria highlighted its partnership with Merck, under which Merck is running a Phase 2 trial of MK-1167 in Alzheimer’s disease and is responsible for all costs; the collaboration includes eligibility for up to $450 million in additional milestone payments plus royalties on net sales of any licensed medicines.
As of June 30, 2025, cash and cash equivalents were $14.2 million. The company expects its current cash position to fund operations through the second fiscal quarter of 2027.
Neuphoria Therapeutics (NEUP) is advancing BNC210, an oral selective negative allosteric modulator of the α7 receptor, across acute social anxiety disorder (SAD) and chronic PTSD programs while maintaining a broader CNS pipeline and partnerships. The Phase 2b ATTUNE PTSD trial met its primary endpoint (CAPS-5 change; p=0.048) with additional statistically significant benefits on depressive symptoms and sleep. PREVAIL narrowly missed its primary public-speaking SUDS endpoint but showed encouraging phase-specific and secondary trends.
The company initiated screening for Phase 3 AFFIRM-1 in SAD targeting ≈332 adults with topline results expected early Q4 2025, and plans a Phase 2b/3 PTSD study contingent on capital. Neuphoria holds multiple patent families with potential protection through 2040, collaborative arrangements including Merck and Carina, and faces typical biotech risks including need for additional capital, regulatory approvals, manufacturing scale-up, and safety monitoring for liver function.
Nasdaq-listed company plans to sell up to $11,494,900 of common stock from time to time through an at-the-market offering agreement with H.C. Wainwright & Co. as sales agent.
This amendment updates the prospectus supplement to reflect the amount of stock the company may sell under General Instruction I.B.6 of Form S-3 and the existing Sales Agreement. As of September 9, 2025, public float was approximately $34,484,701, based on 2,283,755 non-affiliate shares at $15.10 per share, and the company has sold $5,352,879 of common stock under this instruction in the past 12 months.
Sales, if any, will be made as at-the-market offerings under Rule 415, with no minimum sale requirements, and Wainwright earning a 3.0% commission on gross sales while being deemed an underwriter under the Securities Act.
Neuphoria Therapeutics Inc. reports that Nasdaq has accepted its plan to regain compliance with Nasdaq Listing Rule 5620(a), which requires listed companies to hold an annual shareholder meeting within one year of their fiscal year end. The company had previously received a deficiency notice for not holding an annual meeting within twelve months of its fiscal year ended June 30, 2024.
Nasdaq has granted Neuphoria a 180-day extension from the end of that fiscal year, giving the company until December 29, 2025 to regain compliance. Neuphoria states that it intends to file its annual report on Form 10-K on or before September 29, 2025, then file a proxy statement and notice of meeting, and hold its 2025 annual general shareholder meeting within the new compliance period.
Neuphoria Therapeutics insider filing: Spyros Papapetropoulos, President, CEO and director of Neuphoria Therapeutics (NEUP), reported an option grant on 08/27/2025 for 34,559 employee stock options with an exercise price of $8.27 per share. The options vest monthly over four years beginning August 1, 2025, at a rate of 2.0833% of the shares on the last day of each month, and expire on 08/27/2035. After the grant, the reporting person beneficially owns 74,088 shares of common stock directly. The Form 4 was signed on 09/01/2025.